Swiss pharmaceutical giant Roche (SWX: ROG) has released interim Phase III data for its bispecific antibody (BsAb) Vabysmo (faricimab) in the treatment of macular edema resulting from branch and central retinal vein occlusion (BRVO and CRVO). The biologic demonstrated significant vision improvements, with gains of 17 to 19 letters on the eye chart, and a reduction in retinal swelling ranging from 300 to 465 µm within 24 weeks. These benefits were sustained for up to 72 weeks, and Vabysmo showed a favorable tolerability and safety profile throughout the study.
Moreover, treatment intervals could be extended to 3 or 4 months apart for 60% and 48% of BRVO and CRVO patients, respectively, offering a notable advantage over standard therapies that are typically administered every 1 to 2 months.
Currently, Vabysmo is approved for the treatment of neovascular or wet age-related macular degeneration (nAMD) and diabetic macular edema (DME).- Flcube.com
